Arcutis Director Sells $121,000 Amid ZORYVE Revenue Surge
A biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Why Active Funds May Underperform Benchmarks discusses persistent headwinds, costs, and timing issues that hinder outperformance.
26,804 articlesA biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Analysts warn that the stock market’s double bubble could burst if corporate earnings fail to keep pace with lofty pr...
Quantum investing is no longer a dream. This practical guide weighs D-Wave Quantum’s potential, the risks, and steps ...
As EV demand rises, Gentherm faces an earnings path shaped by margins, backlog, and product mix. This guide breaks do...
Nvidia just beat earnings expectations, yet the stock fell in the following days. This article breaks down what the p...
A top executive recently disclosed selling a sizable block of Qualys stock. This article explains how to interpret in...
Investors are eyeing AAR's AIR 2026 earnings call for clues on aftermarket demand, margins, and guidance. This articl...
A bold take from Amazon's CEO on the AI era could shift how investors price the stock. This guide breaks down what an...
Tesla's robotaxi venture is facing real-world hurdles in Texas. This article breaks down what those problems mean for...
A practical, reader-friendly guide to interpreting Xunlei's Q1 2026 earnings. Learn what to watch, how to model resul...
Bark is shaping its path in a competitive pet market. This guide breaks down what to expect in bark (bark) 2026 earni...
Cerebras Systems stock crashed after its latest earnings report, leaving investors asking what happened and what come...